154. Epilepsy with continuous spikes and waves during slow sleep Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 8 Drugs : 2 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
N-[1-((5-cyanopyridin-2-YL)methyl)-1H-pyrazol-3-YL]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide
   Neurocrine Biosciences, Inc.
      2022   Phase 2   EUCTR2021-006788-11-DK   Denmark;Germany;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2021-006788-11-DE   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States
NBI-827104
   Neurocrine Biosciences
      2022   Phase 2   NCT05301894   Denmark;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   NCT04625101   Canada;Denmark;Spain;Switzerland;United Kingdom;United States
   Neurocrine Biosciences, Inc.
      2022   Phase 2   EUCTR2021-006788-11-DK   Denmark;Germany;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003141-11-ES   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003141-11-DK   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2021-006788-11-DE   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2020-003141-11-FR   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2020-003141-11-DE   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States